As a reminder.... below copy/paste from the RLFTF web site. The lawyers working for Dr JJ may wish to call their product a different name (zyesami), however the roots of the nomenclature is "Aviptadil" and "RLF-100". IMO you can't simply rename something with the goal to disassociate to get out of contractual obligations. I think Dr JJ may have surrounded himself with too many greedy lawyers. Dr JJ should follow through with the INTENT of the COLLABORATION AGREEMENT, and behave in honest, good-faith. After all, it was Swiss-based RLFTF that initiated the partnership with NRXP. Not the other way around. At the end of the day, theoretically there could be punitive damages awarded to RLFTF if they can demonstrate that NRXP's actions resulted in financial hardship or losses. JMHO
FROM the RLFTF web site......
What is your IP position for RLF-100™?
Relief holds a patent covering potential formulations of RLF-100™ in the United States valid until at least July 2029, with extension opportunities up to five years as well as in the EU and Rest of World (Great Britain, Germany, Turkey, Spain, Switzerland, Netherlands, Denmark, Ireland, Austria, PRC and Mexico) valid until at least 2026, excluding extension opportunities comparable to the U.S. In part to further build the IP portfolio, Relief and AdVita Lifescience GmbH signed a binding term sheet in January 2021 for Relief to acquire all shares of AdVita. Relief will gain access to all AdVita assets including future pending IP rights that may cover RLF-100™ inhaled formulation specifications for the potential application of inhaled aviptadil in the treatment of lung diseases such as ARDS and pulmonary sarcoidosis.
